Because of the inevitable drug resistance problems, other “molecular surgeries” using CRISPR technology to directly correct or disrupt the mutated site to inactivate the oncogenic activity, might be a more permanent strategy for EGFR-mutant lung cancer treatment.67 The CRISPR technology is poised to open the door to effective personalized cancer treatment from specific applications of genome screening to therapeutic strategies.68 This evidence concerns the gene EGFR and lung cancer.